Masitinib

Overview

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Masitinib in Patients With Mild to Moderate Alzheimer's Disease	2022/10/03	NCT05564169	Phase 3	Not yet recruiting	AB Science
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome	2022/07/08	NCT05449444	Phase 2	Recruiting	AB Science
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis	2022/07/01	NCT05441488	Phase 3	Recruiting	AB Science
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	2021/09/17	NCT05047783	Phase 2	Recruiting	AB Science
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19	2020/11/10	NCT04622865	Phase 2	Recruiting	AB Science
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	2020/04/03	NCT04333108	Phase 3	Recruiting	AB Science
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels	2018/12/10	NCT03771040	Phase 3	Completed	AB Science
Masitinib Plus Gemcitabine in Pancreatic Cancer	2018/12/06	NCT03766295	Phase 3	Completed	AB Science
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer	2018/12/03	NCT03761225	Phase 3	Completed	AB Science
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer	2018/06/14	NCT03556956	Phase 2	Completed	AB Science

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

AB Science's Masitinib Receives FDA and EMA Authorization for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate Cancer

11 days ago

AB Science announced that both FDA and EMA have authorized a confirmatory phase 3 trial of masitinib in combination with docetaxel for metastatic castrate-resistant prostate cancer, using biomarker-driven patient selection.

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment Until 2041

2 months ago

AB Science has received a Chinese patent for its lead compound masitinib to treat COVID-19, providing intellectual property protection until April 2041.

AB Science Secures US Patent for Masitinib in Sickle Cell Disease Treatment Until 2040

3 months ago

AB Science has received a Notice of Allowance from the US Patent Office for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040.

Masitinib Shows Promise in Progressive MS Treatment, Leading Neurologist Highlights Novel Mechanism of Action

4 months ago

Distinguished neurologist Professor Patrick Vermersch identifies mast and microglia cells as key catalysts in neurodegenerative diseases, highlighting their role in conditions like multiple sclerosis and Alzheimer's disease.

EMA's CHMP Recommends 10 New Medicines, Including Novel Therapies and Biosimilars

9 months ago

• The European Medicines Agency's CHMP has recommended 10 new medicines for marketing approval, encompassing five new drugs, one orphan drug, two biosimilars, and two generics. • Novel therapies such as Alhemo (concizumab) for hemophilia and Wainzua (eplontersen) for hereditary transthyretin-mediated amyloidosis received positive opinions. • Biosimilars Absimky (ustekinumab) and Imuldosa (ustekinumab) were recommended for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. • The CHMP reaffirmed its negative recommendation for Masitinib AB Science for amyotrophic lateral sclerosis due to concerns about data reliability and efficacy.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access